113 related articles for article (PubMed ID: 2058321)
1. [Value of pepsinogen I in serum as a screening method for early detection of gastroduodenal lesions and follow-up in therapy with non-steroidal antirheumatic drugs].
Kullich W; Pöllmann G; Zmerekar C; Klein G
Z Rheumatol; 1991; 50(1):39-45. PubMed ID: 2058321
[TBL] [Abstract][Full Text] [Related]
2. [Determination of serum pepsinogen I and II for assessment of gastroduodenal tolerance of S(+) ibuprofen].
Kullich W; Wallner H; Klein G
Wien Klin Wochenschr; 1994; 106(7):208-11. PubMed ID: 8197755
[TBL] [Abstract][Full Text] [Related]
3. [Gastroduodenal tolerance and clinical effectiveness of therapy with lonazolac-calcium in rheumatic diseases].
Kullich W; Fromme K; Klein G
Wien Med Wochenschr; 1996; 146(17):459-64. PubMed ID: 9045528
[TBL] [Abstract][Full Text] [Related]
4. [Changes in the serum pepsinogen level during therapy with acemtacin retard as a measure of gastroduodenal tolerance].
Kullich W; Klein G
Wien Med Wochenschr; 1991; 141(15):331-5. PubMed ID: 1949833
[TBL] [Abstract][Full Text] [Related]
5. Serum pepsinogen I and gastrin in peptic ulcer patients using nonsteroidal anti-inflammatory drugs.
Kemppainen H; Räihä I; Sourander L
Hepatogastroenterology; 1997; 44(16):1143-6. PubMed ID: 9261614
[TBL] [Abstract][Full Text] [Related]
6. [NSAID-induced ulcers--therapy and prevention].
Rösch W
Z Rheumatol; 1995; 54(1):2-8; discussion 9-11. PubMed ID: 7725807
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of peptic ulcer in rheumatoid arthritis.
Tuteja AK; Malviya AN; Bannerjee S; Singh RR; Anand BS
J Assoc Physicians India; 1991 Jul; 39(7):521-2. PubMed ID: 1800492
[TBL] [Abstract][Full Text] [Related]
8. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
[TBL] [Abstract][Full Text] [Related]
9. Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal lesions during treatment with non-steroidal anti-inflammatory drugs (NSAIDs).
Festen HP
Neth J Med; 1989 Dec; 35(5-6):327-33. PubMed ID: 2699655
[TBL] [Abstract][Full Text] [Related]
11. Asymptomatic and symptomatic gastroduodenal patients affected by rheumatic disease treated with non-steroidal anti-inflammatory drugs.
Magarò M; Altomonte L; Zoli A; Mirone L; Berchicci MC; Tricerri A; Corvino G
Panminerva Med; 1989; 31(1):16-8. PubMed ID: 2786181
[TBL] [Abstract][Full Text] [Related]
12. Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.
Miyake K; Ueki N; Suzuki K; Shinji Y; Kusunoki M; Hiratsuka T; Nishigaki H; Tatsuguchi A; Futagami S; Wada K; Tsukui T; Nakajima A; Yoshino S; Sakamoto C
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():67-72. PubMed ID: 15943850
[TBL] [Abstract][Full Text] [Related]
13. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
[TBL] [Abstract][Full Text] [Related]
14. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use.
Larkai EN; Smith JL; Lidsky MD; Graham DY
Am J Gastroenterol; 1987 Nov; 82(11):1153-8. PubMed ID: 3499815
[TBL] [Abstract][Full Text] [Related]
15. [Ranitidine in the therapy and prevention of NSAR-induced (non-steroidal anti-rheumatic agents) gastroduodenal lesions in patients with rheumatism].
Simon B; Bergdolt H; Dammann H; Müller P
Z Gastroenterol; 1991 May; 29(5):217-21. PubMed ID: 1950028
[TBL] [Abstract][Full Text] [Related]
16. [Antirheumatic drug-induced damage of the gastroduodenal mucosa: approach to prevention].
Domschke S; Domschke W
Internist (Berl); 1986 Oct; 27(10):630-6. PubMed ID: 2878905
[No Abstract] [Full Text] [Related]
17. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
Lanas A
Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979
[TBL] [Abstract][Full Text] [Related]
18. NSAID-induced gastric mucosal damage.
Semble EL; Wu WC
Am Fam Physician; 1987 Jun; 35(6):101-8. PubMed ID: 3332745
[TBL] [Abstract][Full Text] [Related]
19. Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study.
Bianchi Porro G; Lazzaroni M; Petrillo M; Manzionna G; Montrone F; Caruso I
Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):43-7. PubMed ID: 9615264
[TBL] [Abstract][Full Text] [Related]
20. Infection with Helicobacter pylori and long-term use of non-steroidal antiinflammatory drugs.
Vcev A; Ivandić A; Vceva A; Stimac D; Takac B; Mikolasević I; Jovanović S; Dmitrović B; Vuković D; Egić B
Acta Med Croatica; 1998; 52(1):27-31. PubMed ID: 9599813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
